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Abstract We have cloned and sequenced the cDNA of the 
human brain ryanodine receptor (RyR3), which is composed of 
4866 amino acids and shares characteristic structural features 
with the rabbit RyR3. Northern blot analysis shows that the 
human RyR3 mRNA is abundantly expressed in hippocampus, 
caudate nucleus and amygdala as well as in skeletal muscle. The 
human RyR3 mRNA is also detected in several cell lines derived 
from human brain tumors. Functional expression of RyR3 and a 
chimeric RyR suggests that RyR3 forms a calcium-release 
channel with a very low Ca2+ sensitivity. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Cytoplasmic Ca2+ plays important roles in cell excitability, 
neurotransmitter release, muscle contraction and other bio-
logical processes [1]. The concentration of cytoplasmic Ca2+ 
can be increased either by Ca2+ entry across the plasma mem-
brane or by Ca2+ release from intracellular stores. While ex-
tracellular Ca2+ enters through voltage-gated Ca2+ channels 
(VGCC) and other types of Ca2+-permeable channels [2], the 
two major classes of intracellular Ca2+ release channels, the 
inositol 1,4,5-trisphosphate receptors (IP3RS) [3] and the rya-
nodine receptors (RyRs), are responsible for Ca2+ release 
from intracellular Ca2+ stores [4-6]. Ca2+ release through 
IP3RS has been observed in many cells, as a ubiquitous mech-
anism to regulate intracellular Ca2+ concentration. On the 
other hand, three types of RyRs, RyRl, RyR2, and RyR3, 
are expressed in specific tissues; RyRl is expressed mainly in 
skeletal muscle [7], RyR2 in cardiac muscle and brain [8] and 
RyR3 in brain and smooth muscle [9,10]. In brain, RyR3 is 
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expressed highly in limited areas which include hippocampus, 
caudate nucleus, corpus callosum, and thalamus [10,11]. Fur-
thermore, RyR3 is also expressed in non-excitable cells [12] 
such as human T-lymphocytes, and is suggested to contribute 
to cell proliferation [13]. 
Successful recombinant expression of RyRl and RyR2 in 
myotubes from RyRl-deficient (dyspedic) mice, homozygous 
for a disrupted skeletal muscle isoform of RyR gene [14], has 
led us to elucidate the indispensable roles of RyRl and RyR2 
in the molecular mechanisms of excitation-contraction cou-
pling in skeletal muscle and in cardiac muscle, respectively 
[15,16]. VGCC directly activates RyRl in skeletal muscle 
[15,17], and possibly in neuron [18], and Ca2+ entering 
through the VGCC is a trigger to open RyR2 in cardiac 
muscle (Ca2+-induced Ca2+ release). Despite the interesting 
distribution of RyR3 expression in brain and in smooth 
muscle, however, functions of RyR3 have remained enigmatic. 
Ca2+ is assumed to be a major physiological ligand for RyR3, 
but several lines of evidence suggest that Ca2+-induced Ca2+ 
release of RyR3 is different from that of other RyRs [9,13,19]. 
An endogenous RyR3 is suggested to be responsible for a 
much lower Ca2+ sensitivity of residual Ca2+ release activity 
observed in skeletal muscle cells from the RyRl-deficient mice 
[19]. RyR3 is insensitive, at least on some occasions, to caf-
feine [9,13], which is the most widely employed compound for 
RyR activation. The fact that RyR3 is expressed in non-ex-
citable cells practically lacking VGCC may even imply that 
RyR3 is regulated by quite different mechanisms from those 
for other types of RyR. Mutant mice lacking RyR3 show no 
gross abnormality except for increased locomotor activity [20]. 
In spite of these circumstantial pieces of evidence, molecular-
physiological properties of RyR3 have remained unclear, 
partly because none of the trials of expressing RyR3 from 
its cDNA in a recombinant expression system has been suc-
cessful so far. Here we have cloned and sequenced the human 
RyR3 cDNA and characterized properties of the human 
RyR3. We have also examined the functional expression of 
the wild-type human RyR3 and a chimeric RyR3-RyR2, using 
myotubes from the RyRl-deficient mice [15]. 
2. Materials and methods 
2.1. cDNA cloning 
Oligo(dT)- and random-primed cDNA libraries, constructed in 
phage XgtlO using poly(A)+ RNA isolated from human brain (cau-
date nucleus) were obtained from Clontech (USA). The cDNA libra-
ries were screened (~3.0X105 plaques) with the Pstl (9790)IEcoRl 
(11834) fragment from the rabbit RyR3 cDNA clone pBRR74 [10] to 
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yield WÚ3RR79; the restriction endonuclease sites are identified by 
numbers (in parentheses) indicating the 5'-terminal nucleotide gener-
ated by cleavage: nucleotide residues are numbered in the 5' to 3' 
direction, beginning with the first residue of the ATG triplet encoding 
the putative initiating methionine. The cDNA insert of WiBRR79 was 
subcloned into the EcoRI site of pBluescript SK~ (Stratagene) to yield 
phBRR79. The library was screened nine times with different probes: 
the 2.4-kbp EcoRI (vector)ADraI (2395) fragment from pBRR331 [10] 
yielded three positive clones including ÀhBRR22, M1BRR6I and 
XhBRR112; the 1.2-kbp PmaCI (4150)1 Aped (5912) fragment from 
pBRR133 [10] yielded A,hBRR51, 52, 53; the 1.3-kbp .EcoRI (vec-
tor)/Ä'«cII (14656) fragment from pBRRHO [10] yielded two positive 
clones including XhBRR91 and MiBRR93; the 1.3-kbp Kpnl (6249)/ 
Hindlll (7523) fragment from pBRR121 [10] and the 1.1-kbp Xbal 
(8405)/PsiI (9494) fragment from pBRR92 [10] yielded MiBRR140, 
JihBRR141 and MiBRR411; the 1.0-kbp EcoRI (vector)/EcoRI 
(13335) fragment from MiBRR93 and the 0.8-kbp Spel (10569)/EcoRI 
(11408) fragment from A,hBRR79 yielded M1BRRI6I; the 0.8-kbp 
EcoRI (vector)/EcoRI (11815) fragment from XhBRR161 yielded 
JihBRR407. Furthermore, two additional clones were derived from 
RT-PCR as follows: 1 ug human brain poly (A)+ RNA (Clontech) 
was subjected to Moloney's murine leukemia virus RNase H reverse 
transcriptase (Gibco BRL) with random primer. The synthesized first 
strand cDNA was amplified with a DNA Thermal Cycler (Perkin-
Elmer Corp.), according to the manufacturer's specifications (Ta-
KaRa LA PCR kit). Following the hot start (1 min at 94°C) the 
samples were subjected to 30 cycles of 20 s at 98°C and, 5 min at 
68°C. Primer pairs for phBRR501 were synthetic 25-nucleotide 
oligomers at bases 2949-2973 (upstream primer, AGTGGA-
TAAACTTGCAGAAAATGCA) and 3495-3519 (downstream pri-
mer, TGGGGAGCTGCTGATCACCAATAAA) of the cloned 
phBRR61 and phBRR51, respectively, and those for phBRR502 
were synthetic 20-nucleotide oligomers at bases 11369-11388 (up-
stream primer, TTGATGAATCTGGACAGCAC) and 12353-12372 
(downstream primer, ACGTGTTAGAAATTGCGGGT) of the 
cloned phBRR79 and phBRR91, respectively. 
The cDNA clones used for nucleotide sequence analysis were as 
follows: phBRR22 (carrying nucleotides - 8 6 to 1263), phBRR61 
(991-3103), phBRR501 (2949-3519), phBRR51 (3435-5253), 
phBRR53 (4444-7346), phBRR411 (7330-9900), phBRR407 (10112-
11814), phBRR79 (8358-11408), phBRR502 (11369-12372) and 
phBRR91 (11468-15486). All cDNA inserts except phBRR501 and 
phBRR502 were subcloned into the EcoRI site of pBluescript SK~. 
The 0.6-kbp Ä'ndlll (2956)/5cfl (3506) fragment of phBRR501 was 
subcloned into the BamHl/Hindlll site, and the 0.5-kbp Apal (11451)/ 
.4ccl (11930) fragment of phBRR502, into the AccVApal site of 
pBluescript SK~. 
Both strands of the resulting cDNA and the reverse transcriptase 
PCR products were sequenced by the dideoxy chain termination 
method [21]. 
2.2. Physiological analysis 
The entire protein coding sequence of the human RyR3 was in-
serted into the EcoRI/NotI site of pCI-neo (Promega) to yield 
phNRR9. The cDNA insert was constructed from the following frag-
ments: EcoRI (vector)/AfroI (1232) derived from MBRR22, Mrol 
(1232)/ffittdIII (2956) from M1BRR6I, Hindlll (2956)IBcä (3506) 
from phBRR501, Ben (3506)/PmaCI (4750) from MiBRR51, PmaCI 
(4750)IPstI (7339) from MiBRR53, Pstl (7339)/CM (9559) from 
A.hBRR411, CM (9559)ISpeI (10569) from MiBRR79, Spel (10569)/ 
Apal (11451) from MiBRR407, Apal (11451)/EcoRI (11815) from 
phBRR502, EcoRI (11815)/EcoRI (14861) from A,hBRR91. The ex-
pression plasmid carrying the chimeric ryanodine receptor cDNA be-
tween the human RyR3 and the rabbit RyR2 was constructed as 
follows. The San (vector)/PmaCI (5038) fragment from the rabbit 
RyR2 cDNA [8] and the PmaCI (4750)/JVbrI (vector) fragment from 
the human RyR3 cDNA were ligated into the SaWNotl site of pCI-
neo. Culture of myotubes from RyRl-deficient (dyspedic) mice and 
cDNA injection were described previously [15]. Fluorescence changes 
(in arbitrary units) were measured after loading Fluo-3 AM into my-
otubes [22]. Caffeine was applied by local ejection from a wide-tipped 
pipette (10-50 |xm diameter). Bath solution was normal rodent Ringer 
which has the following composition (mM): 145 NaCl, 5 KC1, 
2 CaCl2, 1 MgCl2, 10 HEPES, pH 7.4 with NaOH. Temperature 
was 20-22°C. 
2.3. Northern blot analysis 
For Northern blot analysis of human brain and other tissues, sheets 
of multiple tissue Northern (MTN) Blots (Clontech) were purchased. 
Each lane of a sheet of MTN Blots contained approximately 2 u\g of 
poly(A)+ RNA from the following human brain regions; amygdala, 
caudate nucleus, corpus callosum, hippocampus, whole brain, sub-
stantia nigra, subthalamic nucleus and thalamus. Each lane of another 
type of MTN Blots contained approximately 2 ug of poly(A)+ RNA 
from the following human tissues; heart, brain, placenta, lung, liver, 
skeletal muscle, kidney and pancreas. The result of tissue distribution 
was confirmed by an additional sheet of MTN Blots of a different lot. 
Each lane of the blot for cell lines contained approximately 20 |xg of 
total RNA from the following human cell lines, prepared as previ-
ously [10], SK-N-MC (derived from neuroblastoma in origin), IMR-
32 (neuroblastoma), HEL-299 (lung fibroblast), H4 (neuroglioma), 
SK-N-SH (neuroblastoma), HEK-293 (embryonal kidney cell) and 
U373 (astrocytoma). Because probes derived from partial cDNAs of 
the human RyR3 gave only faint signals, the probe used for Northern 
blot analysis was 14.9-kbp Nail (vector)Woil (vector) fragment from 
phNRR9, unless otherwise specified. The probe was generated with 
the Klenow fragment of DNA polymerase and [32P]dCTP [23] by 
random oligonucleotide primer. The blots were hybridized in 50% 
formamide at 42°C and washed three times with 0.3XSSC, 0.1% 
SDS at 50°C. 
2.4. Luminescence assay 
Luminescence assay was carried out as previously [24]. In brief, the 
cells (1 X105 cells/well) were transferred to the calcium assay solution 
with the following condition (mM): 140 NaCl, 5 KC1, 1.5 MgCl2, 2.5 
CaCl2, 5 glucose and 10 HEPES, pH7.4 with NaOH, containing 2.5 
uM coelenterazine, the intermediary substrate of aequorin, and incu-
bated at 37°C for 6 h. The system for luminescence assay was the 
spectrofluorometer CAF-110 (Jasco) [13], connected to luminescence 
unit PL-03 (Jasco). The mobilization of intracellular Ca2+ was initi-
ated by the injection of caffeine (final concentration 10 mM) or rya-
nodine (final concentration 100 |lM). The total amount of aequorin 
activity was measured after permeabilizing the cells with digitonin at a 
final concentration of 200 |Xg/ml. Ethanol concentration was 0.5% or 
less in the cuvette, which did not affect Ca2+ release under these 
experimental conditions. 
3. Results and discussion 
3.1. cDNA sequence and amino acid sequence analysis 
Hybridization screening and sequencing have resulted in 
identification of a number of overlapping cDNA clones. The 
complete nucleotide sequence of the human RyR3 cDNA was 
determined by sequence analysis of nine overlapping clones. 
The primary structure of this protein was deduced by using 
the open reading frame corresponding to the amino acid se-
quence of the rabbit RyR3 [10]. The deduced amino acid 
sequence is 4866 amino acid long with the calculated molec-
ular mass being 551 046. The amino acid sequence comparison 
reveals 96%, 69%, 67% identities, between human RyR3/rab-
bit RyR3, human RyR3/rabbit RyR2, human RyR3/rabbit 
RyRl, respectively. Fig. 1A shows the homology score be-
tween the human RyR3 and the rabbit RyR3 plotted along 
the entire amino acid sequences, demonstrating a high homol-
ogy between the two. Interestingly, however, there are two 
regions of about 20 amino acid residues each, where the ho-
mology score is significantly lower than the rest. The local 
sequence divergence may indicate possibility of alternative 
RNA splicing at those regions. The hydropathicity profile of 
the human RyR3 is similar to those of other RyRs in that 
there is no hydrophobic amino-terminal sequence indicative of 
the signal sequence, that the remaining region is largely hy-
drophilic and that there are four highly hydrophobic segments 
(referred to as Ml , M2, M3 and M4) in the carboxy-terminal 
tenth of the molecule (data not shown). The carboxy-terminal 
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Fig. 1. Amino acid sequence homology between RyRs. The amino 
acid sequence deduced from the human RyR3 was aligned with 
those of the rabbit RyR2 and RyR3, and homology scores between 
the human RyR3 and the rabbit RyR3 (A) and between the human 
RyR3 and the rabbit RyR2 (B) were plotted along the entire se-
quences. Homology score was calculated as a mean of weight values 
in the Dayhoff PAM250 matrix [41] with the window size of 10. A 
gap was treated as one substitution regardless of its length, and its 
weight was assumed to be the minimum value of the matrix. 
region that encompasses the M3 and M4 segments is partic-
ularly well conserved in all RyRs. On the other hand, there 
are rather divergent regions. For example, as in Fig. IB where 
the homology score between the human RyR3 and the rabbit 
RyR2 is plotted, a stretch of about 100 amino acid residues in 
the region around amino acid residue 1300 is missing in 
RyR3; RyR2 has an EF-hand consensus sequence [25] (en-
compassing amino acid residues 1336-1347) [8] and a nucleo-
tide-binding consensus sequence GXGXXG [26] (amino acid 
residues 1324-1329) [8] in this region. Furthermore, the region 
immediately preceding the Ml segment is divergent. The hu-
man RyR3 contains four repeated sequences occurring in two 
tandem pairs (amino acid residues 841-954, 955-1070, 2600-
2711 and 2712-2791), as described for the rabbit RyR2 and 
RyR3 and the human RyRl and RyR2 [8,10,27,28]. 
Arginine residue 613 or 614, replacement of which with 
cysteine in the RyRl has been found to be associated with 
malignant hyperthermia (MH) of swine [29] and human [30], 
is conserved in the three types of RyRs. 
3.2. Functional analysis of RyR3 
Both RyRl and RyR2 mediate release of Ca2+ from intra-
cellular stores, as demonstrated by functional expression of 
the cloned cDNAs [8,31]. Until now, there has been no direct 
demonstration that RyR3 functions as a calcium release chan-
nel. Therefore, we examined functional expression of the hu-
man RyR3, using myotubes from mice lacking skeletal muscle 
isoform of RyR [15]. First, we tried to express the wild-type 
human RyR3 in myotubes from the RyRl-deficient (dyspedic) 
mice by injection of the cDNA into nuclei. But an endogenous 
caffeine response of dyspedic myotubes obscured a difference 
between caffeine responses of non-injected myotubes and of 
myotubes injected with the RyR3 cDNA (10 mM caffeine, 
data not shown). This result was not unexpected because 
the human RyR3 in human T-lymphocytes shows no response 
to caffeine [13]. Since caffeine is believed to exert its activating 
effect on RyR by enhancing Ca2+ sensitivity, we planned to 
confer an effective Ca2+ sensitivity on RyR3 in order to cir-
cumvent the technical difficulties in demonstrating Ca2+-re-
lease activity of RyR3. Considering the possibility that the 
deleted region around amino acid residue 1300 may contain 
a region determining Ca2+ sensitivity, we constructed a chi-
meric RyR molecule so that the missing region is supple-
mented with the sequence of RyR2, which has a high Ca2+ 
sensitivity. The chimeric molecule of the RyR consists of one 
third of the rabbit RyR2 amino acid sequence in the amino-
terminus and two thirds of the human RyR3 sequence in the 
carboxy-terminus (Fig. 2A). Fig. 2B shows a caffeine response 
of the chimeric RyR expressed in dyspedic myotubes. The 
chimeric RyR responded to 1 mM caffeine (Fig. 2B, n = 5 
out of 20). In contrast, the non-injected dyspedic myotubes 
never responded to 1 mM caffeine (Fig. 2B, n = 0 out of 20), 
nor did the dyspedic myotubes injected with the RyR3 cDNA 
to ImM caffeine (data not shown, « = 0 out of 20). Therefore, 
we conclude that the chimeric RyR can produce intracellular 
Ca2+ release channel which can respond to caffeine. 
Based on the structure prediction of RyR from the amino 
acid sequence, the channel-forming region of the RyRs resides 
in the carboxy-terminal tenth of molecule of the RyRs 
[7,8,10,27]. The simplest interpretation of our results is that 
the carboxy-terminal two thirds of the human RyR3 has the 
Ca2+ release channel activity, and that the amino-terminal 
A 
Rabbit RyR2 
Chimeric RyR 
Human RyR3 
B 
t* 
5 s 
Fig. 2. Response to caffeine of a chimeric human RyR3. A: Sche-
matic representation of the structure of the chimeric RyR composed 
of the rabbit RyR2 (open boxes) and the human RyR3 (filled 
boxes). B: Intracellular Ca2+ transients in response to caffeine in 
dyspedic myotubes expressing chimeric the human RyR3. a: Non-
injected dyspedic myotubes never respond to 1 mM caffeine (n = 20). 
b: Dyspedic myotubes in which the chimeric human RyR3 cDNA 
was injected responded to 1 mM caffeine (n = 5 out of 20). Baseline 
shifts may be due to dye bleaching. 
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Fig. 4. Human RyR3 expression in tissues. Northern blot analysis 
of different tissues of human with cDNA probes for the human 
RyR3 mRNAs. 2 ug of poly(A)+ RNA was applied in each lane. 
Autoradiography was performed at — 70°C for 7 days with an inten-
sifying screen. 
Fig. 3. Distribution of human RyR3 in brain. Northern blot analy-
sis of different regions of human brain with cDNA probes for hu-
man RyR3 mRNAs. 2 |xg of poly(A)+ RNA was applied in each 
lane. Autoradiography was performed at — 70°C for 7 days with an 
intensifying screen. 
creased locomotor activity of mice lacking RyR3 may reflect 
the distribution of RyR3 [20]. 
Outside of the brain, an RNA species hybridizable with a 
human RyR3 cDNA probe is detected in skeletal muscle (Fig. 
third of RyR sequence contains the region determining caf-
feine and/or Ca2+ sensitivity. 
3.3. Tissue-specific distribution of RyR3 mRNA 
The tissue-specific transcription of the human RyR3 gene 
was studied by Northern blot analysis of mRNA isolated 
from a variety of human tissues. Although only a weak signal 
is observed when mRNA prepared from whole brain is used, a 
~16-kbp RNA species hybridizable with a human RyR3 
cDNA probe is found abundantly in restricted areas of the 
brain (caudate nucleus, amygdala and hippocampus), and at a 
lower level in corpus callosum, substantia nigra and thalamus 
(Fig. 3). This pattern of the restricted distribution of the 
mRNA expression is similar to that of the rabbit brain 
RyR3 [10,11]. 
This limited distribution of RyR3 in the brain raises a 
number of possibilities. It has been reported that RyR is di-
rectly coupled to the L-type Ca2+ channel also in the brain 
[18]. While the P-type and other types of Ca2+ channels are 
expressed in whole area of brain, the R-type Ca2+ channel is 
expressed highly limited regions of the brain, caudate nucleus 
and hippocampus [32]. A similar distribution of the R-type 
Ca2+ channel and RyR3 leads to a speculation that RyR3 can 
directly interact with the R-type Ca2+ channel in these areas. 
Furthermore, since the regions of RyR3 expression roughly 
correspond to the areas where 'delayed neuronal death' occurs 
after hypoxia in the human brain [10], this type of ryanodine 
receptor may be important in the pathological state. The in-
Fig. 5. Distribution of human RyR3 in human cell lines. Northern 
blot analysis of human RyR3 mRNA expression in rabbit skeletal 
muscle, rabbit heart, rabbit whole brain and human cell lines; neu-
roblastoma (SK-N-MC, IMR-32), lung fibroblast (HEL-299), neuro-
glioma (H4), neuroblastoma (SK-N-SH), embryonal kidney cell 
(HEK293), astrocytoma (U373) with cDNA probes for human 
RyR3 mRNAs. 20 ug of total RNA was applied in each lane. 
Autoradiography was performed at —70°C for 4 days with an inten-
sifying screen. 
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Fig. 6. Intracellular Ca2+ of U373 cells in response to application of caffeine and ryanodine. A: CHO cells transfected with the rabbit RyR2 
cDNA; R3-7 [24] shows a clear increase of intracellular Ca2+ in response to caffeine (n = 11 out of 11). B: Caffeine (10 mM) caused no effect 
in U373 cells (n = 7). C: Examples of responses of U373 cells to ryanodine (100 uJvI). Ryanodine evoked Ca2+ transients variable in amplitude 
(n = 2 out of 4; left and middle traces). Some cells remained refractory to application of ryanodine (n = 2 out of 4; right trace). The variability 
of the responses cannot be ascribed to ryanodine not reaching its site of action as was described previously [31]. Addition of caffeine and rya-
nodine is indicated by bars, cps, counts per second. 
4). The size of the RNA species in these tissues is — 16 kbp, 
the same as in the brain. The faint signals suggest the exist-
ence of RyR3 mRNA in heart. The distribution of mRNA 
outside of the brain is different from that of rabbit, since 
expression of RyR3 can be hardly detected in rabbit skeletal 
muscle [10]. Because RyRl mRNA is plentifully present in 
skeletal muscle, we cannot exclude a small contribution of 
cross-hybridization of the RyR3 probe to RyRl mRNA, 
but the findings that a probe derived from the 3'-non-coding 
region of the human RyR3 cDNA detects signals in skeletal 
muscle (data not shown) and that the heart mRNA gives a 
much lower hybridization signal despite of a similar or even 
slightly higher homology of RyR3 to RyR2 than to RyRl, 
together with isolation of RyR3 cDNA from skeletal muscle 
cDNA library [33], indicate that RyR3 is really expressed in 
the human skeletal muscle. In fact, RyR3 was reported to be 
detected in skeletal muscle in other species, such as mouse 
[34], chicken [35] and bullfrog [36]. 
In non-mammalian skeletal muscle, two types of RyR iso-
forms, oc-isoform (homologous to RyRl) and ß-isoform (ho-
mologous to RyR3), have been identified [36]. In chick skel-
etal muscle, expression of the a- and ß-isoforms is differently 
regulated in the stages of development. Therefore these two 
types of isoforms are thought to have different roles in skeletal 
muscle [35,37]. The different contents of RyR3 gene products 
are also observed in mammalian skeletal muscle, being more 
abundant in the diaphragm and soleus, and at a lesser level in 
the extensor digitorum longus [33]. In this study, we showed 
that RyR3 expression is much higher in human skeletal 
muscle than in rabbit skeletal muscle [10]. This observation 
suggests that the expression level of RyR3 in skeletal muscle 
varies among mammalian species, although the possibility 
that the differential tissue distribution of RyR3 accounts for 
this observation cannot be excluded. It is well known that an 
acute increase of intracellular Ca2+ in human skeletal muscle 
causes MH [30]. Although MH is reported to be associated 
with the mutation of RyRl [38], only 5% of MH have the 
mutation of Arg to Cys substitution at position 614 in RyRl 
gene [30,39]. The abundant expression of RyR3 in human 
skeletal muscle raises a possibility of involvement of RyR3 
in a variant form of MH. RyR3 may be also related to other 
disorders of intracellular Ca2+ regulation, such as central core 
disease [39] and neuroleptic malignant syndrome [40]. 
We have evaluated human cell lines originating from brain 
tumors, since the tissue-specific distribution of the RyRs in 
the human brain may represent cell-specific Ca2+ regulation 
related to proliferation. The RyR3 mRNA is found to be 
expressed in several human cell lines (Fig. 5). Abundant ex-
pression is observed in U373, a cell line originating from a 
malignant astrocytoma, weak expression is detected in IMR-
32, derived from a malignant neuroblastoma, and faint ex-
pression in H4 from a malignant neuroglioma. Although 
RyR2 expression is detected in IMR-32, expression of other 
types of RyRs is not detected in U373 or H4 (data not 
shown). Expression of RyR3 is not detected in SK-N-MC 
or SK-N-SH, although these cell lines are also malignant neu-
ronal cells in origin. 
There was an increase of intracellular Ca2+ in U373 and 
H4, in response to ryanodine but not to caffeine, although in 
the same experimental condition, caffeine response was always 
observed in CHO cells expressing the rabbit RyR2 [24] (Fig. 
6). The positive ryanodine response and the negative caffeine 
response of U373 and H4 are the same as observed for T-
lymphocytes, which are features distinguishing RyR3 [13]. The 
Ca2+ sensitivity of Ca2+-induced Ca2+ release of the endoge-
nous RyR3 observed in muscle cells from the RyRl-deficient 
mice is reported to be significantly lower than that of RyRl 
[19]. Together with the results of expression of the RyR3 and 
the chimeric RyR, we conclude that RyR3 has a very low 
caffeine and/or Ca2+ sensitivity. Since it is questionable 
whether a Ca2+ concentration high enough to activate 
RyR3 can be attained in physiological conditions, it is intri-
guing to speculate that RyR3 may have a different activation 
mechanism. In pathological situations, however, when such a 
162 Y. Nakashima et al.lFEBS Letters 417 (1997) 157-162 
high Ca2+ concentration happens to occur, RyR3 may take 
part in maintaining and spreading pathological states. 
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